StockData

Ascentage Pharma Group International vs Arcutis Biotherapeutics

AAPG and ARQT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AAPG and ARQT compare

Arcutis Biotherapeutics grew revenue faster over the last twelve months (76.1% versus −41.5% for Ascentage Pharma Group International).

Arcutis Biotherapeutics keeps more of each dollar of sales as profit, with a net margin of 6.1% compared with −216% at Ascentage Pharma Group International.

Arcutis Biotherapeutics scores higher on the StockData Score (11 against 3 for Ascentage Pharma Group International), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAAPGARQT
Size and price
Market cap–$3.4B
Share price$13.14$27.33
Change, 1 year−61.7%9.3%
Change, 5 years–63.9%
Beta (5Y)1.431.16
Employees767354
StockData Score
Total score311 (better)
Valuation score00
Growth score14 (better)
Performance score14 (better)
Health score13 (better)
Dividend score00
Valuation
P/E–124×
P/S–7.4×
P/B–15.6×
EV/EBITDA–96.5×
P/FCF–87.7×
FCF yield–1.1%
Fair value–$5.43
Margin of safety–−403%
Growth
Revenue growth (TTM)−41.5%76.1% (better)
Profitability
Gross margin91.5% (better)91.1%
Operating margin–7.4%
Net margin−216%6.1% (better)
FCF margin−209%8.4% (better)
Return on equity−156%15.9% (better)
Return on invested capital–36.9%
Financial health
Debt / equity1.500.49 (better)
Net debt / EBITDA–−3.79
Interest coverage–2.5×
Current ratio1.792.92 (better)
Altman Z-score–6.38
Piotroski F-score–4
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions0.00%105%
Held by insiders13.0%9.3%
Insider net buying, 12 months–−$11.1M
Short interest, % of float–15.9%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.